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Abstract 
Purpose. Retinitis Pigmentosa (RP) relates to a heterogeneous group of blinding 
diseases, which collectively affect about 1 in 4000 individuals worldwide. The large 
genetic diversity in the mutations causing RP, even when affecting the same gene, leads 
to very different degeneration phenotypes. Previously, research on Pde6 mutant animals 
has focused on Pde6b mutants (Keeler 1924, Chang, Hawes et al. 2002). Pde6a mutants 
have been far less studied, although mutations in the Pde6a gene can also cause the 
death of rod photoreceptors and RP.   
Methods. Our experiments were divided into two steps: Characterization of retinal 
degeneration in vivo, and treatment of Pde6a mutants in in vitro condition.  With the 
characterization of retinal degeneration in vivo, we used different homozygous pde6a 
mutant mice. Namely, the V685M, D670G, R562W, and V685M*R562W variants.  We used 
a variety of degeneration markers (i.e. TUNEL, Caspase-3, Calpain activity, PARP activity, 
PAR accumulation) to study the progression in photoreceptor degeneration of these 
Pde6a mutants at different post-natal (PN) days in vivo.  With the treatment of Pde6a 
mutants in vitro condition, we used organotypic retinal explant cultures treated with the 
PARP specific inhibitor PJ34 to confirm the causal involvement of PARP activity in the 
neurodegenerative process. 
Results. Our study indicated that the speed of retinal degeneration varied in the four 
Pde6a mutant situations in vivo, the progression of photoreceptor degeneration was 
always correlated in time with an excessive activation of Calpain and PARP, 
accumulation of PAR, positive reaction in the TUNEL assay, but activation of Caspase-3 
was not detected. Organotypic retinal explant cultures treated in vitro with PJ34 
showed a significant increase in the number of surviving photoreceptors in 
V685M*R562W, R562W, and D670G retinae. However, in the V685M mutant, there was 
no significant difference between both of groups. 
Conclusion. We showed that Calpain, PARP, and PAR play a dominant role in the 
mechanism of photoreceptor degeneration in different Pde6a mutants. We highlight 
PARP as a common target for neuroprotective interventions in RP caused by Pde6a 
mutations. Furthermore, our study may serve to predict time-courses of retinal 
degeneration in human RP patients suffering from Pde6a mutations and could help to 
define the optimal time-points for clinical interventions.  
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1. Introduction 
1.1 Retinal structure and visual transmission in vertebrates 
1.1.1 Overview of the vertebrate retina 
 The anatomical structure of the vertebrate retina is comprised of 10 layers (The Retinal 
Tunic. Virginia-Maryland Regional College of Veterinary Medicine). These layers are : 
The retinal pigment epithelium (RPE), the photoreceptor layer (PL), the external 
limiting membrane (ELM), the outer nuclear layer (ONL), the outer plexiform layer 
(OPL), the inner nuclear layer (INL), the inner plexiform layer (IPL), the ganglion cell 
layer (GCL), the nerve fiber layer (NFL) and the inner limiting membrane (ILM). 
 
 
Figure 1. Cross-section of the retina 
The photoreceptors (rods and cones) convert photons into neurochemical energy, which 
is relayed through the retina. The different layers of the retina process the image signal. 
The output of the retina comes from the retinal ganglion cells, whose axons gather at the 
optic disc to form the optic nerve. In retinitis pigmentosa and age-related macular 
degeneration, the photoreceptors are degenerated but the other layers of the retina 
remain functional. (Image is taken from www.webvision.med.utah.edu.) 
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The Inner limiting membrane (ILM) is essentially a base membrane, which is the 
innermost layer, and is formed by the end feet of Müller cells. Its function is to separate 
the retina from the vitreous. The Nerve fiber layer (NFL) is formed by the axons of 
ganglion cells, running between this layer and the ILM. It passes in parallel through the 
lamina cribrosa to form the optic nerve. The Ganglion cell layer (GCL) is formed by the 
somas of retinal ganglion cells whose axons form the optic nerve.  It mainly contains two 
types of ganglion cells, the midget ganglion cells that are present in the macular region 
and polysynaptic ganglion, which lie predominantly in the peripheral retina. 
The Inner plexiform layer (IPL) is a nerve fiber layer where the synapses between 
bipolar cells, amacrine cells, and ganglion cells are located. The Inner nuclear layer (INL) 
mainly consists of the nuclei of bipolar and amacrine cells, which are surrounded by 
capillaries in the central retina, and nuclei of avascular amacrine cells in the outer layer. 
The Outer plexiform layer (OPL) consists mainly of connections of rod spherules with 
the dendrites of bipolar cells, and cone pedicles with horizontal cells.  
The Outer nuclear layer (ONL) consists of cells bodies of both rod and cone 
photoreceptors, which contain a photosensitive substance, rhodopsin, which 
participates in peripheral and scotopic vision: and cones; which also contain a 
photosensitive pigment and are primarily responsible for central and color vision. The 
External limiting membrane (ELM) is a fenestrated membrane that separates the inner 
segments of photoreceptors from their nucleus and allows both the rods and cones to 
maintain their structure through mechanical strength. The Retinal pigment epithelium 
(RPE) is the outermost layer of the retina, and consists of a single layer of cells 
containing the pigment melanin. 
There are only 1.2 million optic nerves even though there are 130 million photoreceptor 
cells in the human retina. Vision is formed after light reaches the retina and the 
transduction of visual stimuli to electrical stimuli begins. This transduction of visual 
signals relies on the physiological state of each cell. There are two sorts of photoreceptor 
cells existing in the retina, rods and cones.  Rods, which have higher sensitive to light but 
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fail to provide for highly discriminated central vision, and the cones which only account 
for 3% of total retinal photoreceptor cells (Szel and Rohlich 1992), and are mainly 
responsible for high discrimination in central vision, color vision and photopic vision. 
Signals of rod and cone cells take relatively independent positions in the transduction 
pathway of retina. 
1.1.2 Visual Transmission in vertebrate 
Visual photo-transduction is a process, which first takes light into the eye, then a 
biological conversion of that light transfers it into an electrical signal in the retina 
through the rhodopsin pathway. Subsequently, rhodopsin is rapidly decomposed into 
opsin and retinene. Opsin activates the protein transducin and binds GTP, and then the 
GTP-α complex activates phosphodiesterase (PDE). This leads to cGMP break down to 
5’- GMP through the Na+ pathway, as PDE hydrolyzes cGMP. Reduced levels of cGMP 
cause cyclic nucleotide gated channels to close preventing influx of Na+ and Ca2+. The 
extracellular influx of Ca+ through L-type Ca+ channels is the requirement for the 
photoreceptor cells to release glutamic acid. However, a L-type Ca+ pathway gene 
mutation will lead to blindness (Schmitz and Witkovsky 1997)  
Vision results from the decomposition of rhodopsin, a pigment molecule that is 
extremely sensitive to light. The cones pigment is a chemical substance of the outer 
segment membrane; it is similar to the rhodopsin in the rods, and is also responsible for 
color vision and contains the same chemical, retinene. Primates have three principal 
color receptors in their retina. These three types of cones are sensitive for light at 
different wave-lengths; short-wavelength (S-cones 440nm) sensitive, or blue light, 
middle-wave-length (M-cones 545nm) sensitive for green light and long-wavelength (L-
cones 565nm) sensitive for red light, respectively. Perception of color can be 
synthesized by these three principal color receptors for individual colors. Though coded 
by these three different colors, the human eye is able to perceive a wide range of colors. 
While the greatest difference between cone and rod cells is the mechanism for 
photoelectric conversion that they employ, cone bipolar cells also make synaptic 
connections with the dendrites of ganglion cells without passing through the loop of an 
amacrine cell, as in the rod pathway. Consequently, the cone pathway features 
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advantageous characteristics such as being more direct and having a smaller 
convergence.   
There are several varieties of proteins participating in photoelectric conversion, the 
accurate functions of some of which are still not unknown. In the case of changes in the 
structure and function of photoreceptor cells and their internal signaling molecules due 
to gene mutation and environmental damage, the photoreceptor cells function will 
become abnormal and even incurs apoptosis. It is important to indicate that any 
abnormality in quality and quantity of any molecule will influence the light transduction 
process. The pathological change of retinal pigment degeneration results from the 
dysfunction of the rod cells. 
1.2 Retinitis Pigmentosa. Disease Pathology and Genetics 
1.2.1 Clinical presentation and histopathologic of retinitis pigmentosa 
Retinitis Pigmentosa (RP) is a hereditary neurodegenerative disease of the retina, which 
affects photoreceptors and is a major cause of early-onset blindness in the industrialized 
world. In the clinic, the fundus of Retinitis pigmentosa patients include attenuated 
vasculature, intraretinal pigmentary deposits and bone spicules. When pale optic disc 
symptoms emerge, it usually means the patient is often already in an advanced disease 
stage. Retinal pigmentation, attenuated vasculature, together with the pale optic disc, 
made up what is called the RP triad. 
In typical cases, the retinal pigment degeneration first affects rods. Due to the abnormal 
toxic effect of proteins or due to abnormal enzymatic activity, the rod outer segments 
(OS) are reduced and gradually shortened; the internal structure of OS is reshaped, 
followed by opsin rearranged to the inner segment (IS); and finally the axon retreats 
from the synaptic connections in the OPL. Eventually, the cones will suffer from 
secondary death (Marc, Jones et al. 2007). Photoreceptor cell degeneration mainly 
presents from the perspective of tissue pathology, the outer nuclear layer will become 
thin and disappear and the outer plexiform layer and other relevant tissues and cells of 
the retina will change secondarily. Clinically, pathogenic locations are generally seen at 
the equator of the retina, which corresponds to the distribution of rods in the retina. 
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There are very few rod cells in the fovea of the retina, however, their density reaches a 
maximum at 20° from the center and is gradually reduced outwards. Therefore, the 
disease is often characterized by a ring scotoma. However, cone cells incur secondary 
death after the degeneration of rod cells in hereditary retinal pigment degeneration, 
which may be associated with the oxidative damage and interaction of cone and rod cells 
(Mohand-Said, Hicks et al. 2000, Ying, Jansen et al. 2000, Yu and Cringle 2005). 
 
                                                                                 
 
Figure 2.Photographs of a Retinitis pigmentosa retina 
Photographs of the retinitis pigmentosa retina (left) and normal (right). Typical RP 
features are evident in the affected retina (upper left) including marked pigment 
epithelial thinning, retinal vascular attenuation, classical 'bone spicule' and intraretinal 
pigmentary deposits (Image taken from: 
www.rpfightingblindness.org.uk/index.php?tln=aboutrp&pageid=71). 
1.2.2 Genetics of retinitis pigmentosa 
Retinal pigmentosa refers to a highly hereditary heterogeneous disease, which is 
characterized by degeneration due to rod photoreceptor cell damage. The retina suffers 
from internal damage and neuroglia hyperplasia and finally severe visual dysfunction is 
presented due to the cone photoreceptor cell death (Fariss, Li et al. 2000, Hartong, 
Berson et al. 2006). The disease is divided into autosomal recessive (AR), approximately 
50-60%; autosomal dominant (AD), about 30-40%; and dominant X-linked (XL) 
hereditary, around 5-15% (Hartong, Berson et al. 2006, Chizzolini, Galan et al. 2011). 
There are over 67 known RP causative genes (https://sph.uth.edu/retnet/sumdis.htm), 
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of which 23 are autosomal dominant hereditary genes, 41 are autosomal recessive 
hereditary genes and 3 are dominant X-linked genes, of which Pde6a is an autosomal 
dominant. A study conducted an SSCP analysis of 22 exons of 164 irrelevant patients 
Pde6a gene and a sequence testing of abnormal variants. They found 8 different mutant 
diseases in 6 ARRP families, of which 2 are nonsense mutations and 5 are missense 
mutations. One mutation influences the classic splice donor site, thus 3-4% of ARRP 
patients in North America are affected by the Pde6a gene mutation (Dryja, Rucinski et al. 
1999).  
1.3 Phosphodiesterase (PDE) in retinal degeneration 
Phosphodiesterase (PDE’s) regulates the levels of the signaling molecule cAMP 
(guanylate cyclase-activating protein) and cGMP (cyclic guanosine monophosphate). In 
photoreceptors, PDE6 hydrolyses cGMP, which is the key signaling molecule in the 
vertebrate photo-transduction cascade. According to the different forms of the protein, 
PDE6 could be divided into rod-PDE6 and cone-PDE6. Retinal rod cell holoenzyme refers 
to a tetramer composite, consisting of two larger catalytic subunits (α and β) and two 
smaller regulatory subunits (γ), respectively encoded by Pde6a, Pde6b, Pde6g genes. All 
mutations occurring in any of the three PDE6 subunits together may be responsible for 
up to 10% of human RP patients (Bayes, Giordano et al. 1995, Tsang, Gouras et al. 1996, 
Dryja, Rucinski et al. 1999). 
cGMP is an essential target for phosphodiesterase in the vertebrate retina and its 
contribution to sensitivity regulation in rods (Koutalos, Nakatani et al. 1995). 
Photoexcitation in vertebrate rod photoreceptor cells occurs through a light-activated 
cGMP enzyme cascade. Absorption of a photon by the receptor molecule rhodopsin, 
leads to the activation of a potential cGMP phosphodiesterase, which rapidly hydrolyzes 
cytosolic cGMP. The transient decrease of cGMP concentration causes the closure of the 
cGMP-sensitive channels on the plasma membrane and results in hyperpolarization of 
the cell (Fesenko, Kolesnikov et al. 1985, Liebman 1987). Its dynamic concentration is 
made of hydrolysis of Pde6a (Phosphodiesterase 6a-subunit) and cGMP, which is a key 
subunit for transducin, and the process of participating in visual signal transduction. 
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Pde6-a gene mutation has already been confirmed as one of the factors causing 
autosomal recessive retinal inflammation (provided by RefSeq, Jul. 2008). 
1.4 Animal models for retinitis pigmentosa 
Hereditary retinal degenerations are a group of blinding eye diseases with the 
progressive loss of photoreceptor cells indicated as its main characteristic. Though 
many disease-causing genes have already been confirmed, the mechanism of the 
photoreceptor death caused by gene defect still remains unknown. Therefore, there is no 
effective therapy at present. Further, it is hard to collect materials for retinal 
degeneration of human genetics (especially RP), so research mainly relies on animal 
models to probe its pathological process and pathogenesis. Previously, PDE6 
dysfunction was investigated primarily on animal models affected by mutations in the 
Pde6b gene, such as the rd1 (Keeler 1924) or the rd10 mouse (Chang, Hawes et al. 2002). 
A variety of Pde6a mutations are also known to cause RP (Sakamoto, McCluskey et al. 
2009), but so far these have been relatively little studied. 
1.4.1 Retinal degeneration models. Pde6a Mice 
The Pde6a mice carry a loss-of-function mutation in the gene for the alpha-subunit of the 
rod photoreceptor cGMP phosphodiesterase 6 (Pde6-a). Different Pde6a mutations in 
the animal may contribute to the differences in the mechanisms in rods and cones in 
various ways. Here, we used four different animal models to try to understand 
photoreceptor cell death mechanisms.  All Pde6a mutants used were of the C57BI6/J 
strain. Three out of four models with Pde6a mutations, homozygous D670 and V685, 
have been identified in a G3 ethyl nitrosourea (ENU) mutagenesis screen, and generated 
a new mouse model for the R562W mutation. The original residues mutated in these 
Pde6a models encode for amino acids that are highly conserved across species both at 
the nucleotide and amino acid level. Mice with abnormal fundus pigmentation were 
observed by indirect ophthalmoscopy in a colony of ENU mutagenized G3 A.B6-Tyr+/J 
mice in the Neuroscience Mutagenesis Facility (NMF) at The Jackson Laboratory. Based 
on the homozygous mutants, we then generated compound heterozygous 
Pde6aV685M*R562W. The homozygous Pde6aR562W, which reproduces the human blinding 
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disease retinitis pigmentosa, was obtained from the company GenOway (Sakamoto, 
McCluskey et al. 2009). 
Table 1.Animal models used in the study 
Official Line Designation Genetic defect Source 
V685M mutation in alpha-subunit of 
the rod photoreceptor cGMP 
phosphodiesterase 6  
Jackson Laboratory 
V685M*R562W Tübingen university 
R562W GenOway 
D670G Jackson Laboratory 
C57BI6/J Wild type Jackson Laboratory 
 
 
Figure 3.The V685M mice 
The V685M mice were obtained from Jackson Labs (Bar Harbor, MA, USA) (Stock No. 
006026). Pde6aV685M and have been identified by the fine structure map containing 12 
genes, according to the Ensembl database (http://www.ensembl.org), including Pde6a, 
an excellent candidate gene. Sequencing of both Pde6a cDNA and genomic DNA from 
A.B6-Tyrþ/J-Pde6anmf282/nmf282 mice revealed a single nucleotide G to A missense 
mutation in exon 16, which is predicted to cause an amino acid change from valine to 
methionine (V685M). The valine residue is highly conserved among zebrafish, mouse, 
dog, human and bovine, suggesting its importance in the catalytic function of Pde6a 
(Sakamoto, McCluskey et al. 2009). 
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Figure 4.The D670G mice 
The cDNA and genomic DNA of D670G were from C57BL/6J Pde6anmf363/nmf363 mice and 
were directly sequenced for altered fundus pigmentation (Sakamoto, McCluskey et al. 
2009). ENU mutagenesis was used to create an A to G transition that results in an amino 
acid substitution of glycine for aspartic acid at position 670 (D670G) in Pde6a. This 
Pde6anmf363 mutation, is located in the catalytic domain of Pde6a, and is 15 amino acids 
away from the Pde6anmf282 mutation. The aspartic acid residue at position 670 is also 
highly conserved among zebrafish, mouse, and dog, human and bovine (Sakamoto, 
McCluskey et al. 2009). Pde6aD670G mice were provided by Jackson Labs (Bar Harbor, MA, 
USA) (MGI ID: 3828520).  
Despite the fact that these mutations are located within the catalytic domain of the 
Pde6a protein, the biochemical consequences of the mutations differ (Sakamoto, 
McCluskey et al. 2009). The valine 685 residues in Pde6aV685M are more important than 
Pde6aD670G. 
 
Figure 5.The R562W mice 
The R562W knock-in mutant was generated by Genoway (Lyon, France).  The generation 
of this mutant followed the identification of a human RP patient with compound 
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heterozygous for the c.1684C>T/p. Arg562Trp and c.2053G>A/p. Val685Met mutations 
in Pde6a. 
To identify the homozygous Pde6aR562W animals, the progeny resulting from the F2 
breeding mice was screened using a PCR specific for the wild-type Pde6a allele. For the 
detection of the point mutant Knock-in allele, the primer set 87213oth-PDF1/87214oth-
PDF1 was designed flanking the remaining loxP site. 
 
Figure 6.The V685M*R562W mice 
RP animal models are normally studied in the homozygous state, even though in human 
RP patients, homozygosity is relatively rare and, in fact, compound heterozygosity, 
where two different disease causing alleles come together in one individual, is more 
common. Therefore, crossbreeding of the Pde6aR562W knock-in with the Pde6aV685M 
mutant, gave the opportunity to recreate and study an actual patient genotype. This 
animal model is exactly homologous to a human RP patient genotype and represents one 
of the first ever attempts to create a patient matched animal model for the development 
and assessment of an individualized therapy for RP. The generation of this mutant 
followed the identification of a human RP patient who was compound heterozygous for 
the e.1684C>T/p. Arg562Trp and e.2053G>A/p.  
1.5 Calpain family  
It was officially named Calpain or calcium activated neutral protease (CANP) in 1991 
(Guroff 1964), and was first isolated and purified in the skeletal muscle of the chicken in 
1978 (Ishiura, Murofushi et al. 1978). The cDNA of the enzyme was first cloned in 1984 
(Ohno, Emori et al. 1984). Calpain is a type of non-soluble restriction proteolytic enzyme 
that exists in almost all mammalian cells. It belongs to a family of at least 16 members of 
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calcium-dependent cysteine proteases (Huang and Wang 2001). In mammals, the two 
major isoforms, Calpain1 (µ-Calpain) (Kishimoto, Kajikawa et al. 1981) and Calpain2 (m-
Calpain) (Dayton, Goll et al. 1976) are activated by micro molar and millimolar Ca2+ 
concentrations, respectively. According to their histological distribution, the Calpain 
family is divided into two categories. Specific Calpains includes Calpain3 (skeletal 
muscle), Calpain8 (smooth muscle), Calpain9 (stomach), and non-specific Calpains, such 
as Calpain1, 2, 10 etc. The physiological role of Calpain is still poorly understood, but 
they have been shown to be active participants in processes of cell mobility and cell 
cycle progression (Hood, Brooks et al. 2006). 
1.5.1 Calpain in neuronal and inherited retinal degeneration           
Calpain as a calcium-binding protein has been shown to have a direct correlation with 
cell death. In certain conditions, when the concentration of intracellular Ca2+ is increased 
(Azarian, Schlamp et al. 1993, Gressner, Lahme et al. 1997), it can cause Ca2+ overload in 
mitochondria, activate the mitochondrial Calpain and trigger the cell death (Kar, 
Samanta et al. 2010). Na+/Ca+ exchanger (NCX) is the main channel for the 
mitochondrial calcium clearance, along with the inducement of the death of smooth 
muscle cells (Kar, Chakraborti et al. 2009). Another pathway of cell death is dependent 
on Apoptosis-Inducing Factors (AIF), which are released from the mitochondrial 
membrane; apoptotic signaling can be divided into Caspase-dependent and Caspase-
independent pathways. Apoptotic protein Cyt-C, apoptosis protease activating factor-1 
(APAF-1), and procaspase 9 activate Caspase 9 and trigger downstream Caspase events, 
which constitute the route of classic mitochondrial apoptosis (Marek 2013). 
Calpain plays an important role in intracellular signaling and calcium-induced neuronal 
degeneration as a calcium dependent cytosolic protease (Saito, Elce et al. 1993). The 
main cause of the RP disease is the specific expression of a gene mutation in the 
photoreceptor cells, and studies have shown that the ultimate way is apoptosis 
(Papermaster and Windle 1995). It is an important key in prevention and treatment of 
RP to understand how the genetic mutations produce and affect the factors, which 
induce the cell death of retinal cells. Calpain is directly correlated with cell death as a 
Ca2+ -binding protein. When Ca2+ concentration is elevated, the combination of Calpain 
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and Ca2+ activate the Calpain and participate and promote the apoptosis. The elevated 
level of the Ca2+ has been shown to be proportional to cell death as well as non-inherited 
models of RP (McConkey, Nicotera et al. 1989, Azarian, Schlamp et al. 1993, Gressner, 
Lahme et al. 1997). Ca2+ dependent Calpain-type proteases are ubiquitously expressed 
and are involved in neurodegeneration, including the retina and is usually associated 
with alternative non-apoptotic cell death mechanisms (Paquet-Durand, Azadi et al. 2006, 
Paquet-Durand, Sanges et al. 2010). Numerous studies have shown that Calpain activity 
is increased in many animal models for retinal degeneration including Balb/c mice, rd, 
WBN/Kob rats, rd1, rd10, nmf137 (Donovan and Cotter 2002, Doonan, Donovan et al. 
2003, Azuma, Sakamoto-Mizutani et al. 2004, Paquet-Durand, Azadi et al. 2006). The 
localization of Calpain activity is of major importance both for our understanding of the 
degenerative mechanisms and the assessment of potential neuroprotective treatments 
(Paquet-Durand, Silva et al. 2007). However, what part does Calpain play in retinal 
photoreceptor degeneration in Pde6a mutants, which have not been described 
previously?  
1.5.2 Caspase-dependent apoptosis 
Apoptosis is an extremely complex process, which requires a variety of factors to occur, 
such as pro-apoptotic factors and anti-apoptosis factors that eventually lead to 
apoptosis through a variety of ways. Calpain may interact with Caspases in a direct or 
indirect way, depending on the tissue specificity and difference in conditions. They have 
many common substrates. Enhancing the activity of Caspase-3 may reduce the 
intracellular level of Calpastatin that can indirectly promote the Calpain activation. 
Calpain can further cleave and prevent the activation of caspases (Nelson, Smuder et al. 
2012). In the apoptosis of neuronal cells, Calpain cleaves and deactivates Caspases, but 
the activation can also be blocked by Calpain inhibition (Martinez, Zhang et al. 2010, 
Boehmerle and Endres 2011). 
1.5.3 Caspase-independent apoptosis 
Cells which are initially stimulated by apoptotic factors may see their intracellular Ca+ 
levels rise causing the activation of mitochondrial µ-Calpain.  This cleaves AIF 
(Apoptosis-Inducing Factor) (62ku), which is a Caspase-independent death effector. 
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Afterward, the cells generate tAIF (57ku) and are detached from the inner mitochondrial 
membrane into the gap between the membranes, which can cause chromosome 
condensation and DNA degradation, finally leading to cell apoptosis (Chen, Paillard et al. 
2011). Calpains may be the most important enzymes during the process of cleaving and 
releasing (Norberg, Orrenius et al. 2010). Therefore, to understand the function of 
mitochondrial Calpain in the regulation of cell apoptosis can not only contribute to the 
understanding of the molecular mechanisms of cell death, but may also provide new 
ideas for the development of drugs to eliminate Ca2+ overload and use selective Calpain 
inhibitors for the treatment of neurodegenerative diseases. 
1.6 Poly-ADP-Ribose Polymerase (PARP) family 
Poly-ADP-Ribose Polymerase (PARP) is a highly conserved nuclear enzyme in the 
eukaryotic cell. The PARP family is composed at least 18 different enzymes and plays an 
important role in DNA repair, replication, genome stability, regulation of cell 
proliferation and differentiation (Herceg and Wang 2001).  
 
Figure 7.The multifaceted nature of PARP  
Schematic delineation of the multifaceted nature of Poly (ADP) Ribose Polymerase 
(PARP), which include DNA repair, Chromatin Modification, Inflammation, 
Transcriptional Regulation, and Cell Death. Figure adapted from (Swindall, Stanley et al. 
2013). 
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PARP-1 is one member of the PARP family (Malanga and Althaus 2005) and is a nuclear 
enzyme present in the nucleus, which is responsible for DNA repair and protein 
modification. PARP-1 contains a DNA-Binding domain, an auto-modification domain and 
a C-terminal catalytic domain. The relative molecular weight of that is 116,000 Dalton. 
Nuclear DNA damage and DNA breaks can lead to excessive PARP activation, which 
causes excessive NAD+ utilization (nicotine amide adenine dinucleotide). Therefore, ATP 
(adenosine-5’-triphosphate) levels become depleted, leading to an energetic collapse 
and finally cell death. PARP is a critical factor during the cell death that involves 
accumulation of PAR (poly-ADP-ribose) and nuclear translocation of AIF (apoptosis 
inducing factor) from mitochondria. Excessive production of PAR by PARP-1 in response 
to extensive DNA damage may facilitate activation of different proteins, including DNA 
polymerases, topoisomerases, and transcription factors. PARP1 itself can also be down 
regulated by transfer ADP- ribose units from NAD+, thus participating in the mechanism 
of DNA repair (Petrucco and Percudani 2008, Langelier, Planck et al. 2012). 
Previous studies showed that the over activation of PARP may not only help to repair 
DNA damage, but could also cause further damage by reducing DNA stability and 
causing inflammation due to energetic collapse (Swindall, Stanley et al. 2013), In 
addition, excessive PARP-1 activation may also cause cell death independent of energy 
collapse due to a toxic level of PAR. Numerous studies showed that excessive PARP 
activation in the nucleus constitutes a nuclear signal that reaches to mitochondria 
(Berger, Sims et al. 1983), one route to cell death through PARP mediation may cause 
mitochondrial membrane depolarization and open the MPTP (mitochondrial 
permeability transition pores) (Sims, Berger et al. 1983, Du, Zhang et al. 2003), and 
finally cause DNA damage (Wang, Dawson et al. 2009). These studies indicated PARP as 
an important therapeutic target for the nervous system and other diseases associated 
with energy failure, for instance, RP. Therefore, further investigation is needed in more 
animal models, for example in Pde6a mutants. 
1.6.1The role of the PARP in retinal degeneration 
PARP plays a double role of DNA repair and protection of cells from toxic effects 
(Dantzer, Ame et al. 2006). Excessive activation of PARP not only plays an important 
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role in many neurodegenerative diseases (Wang, Dawson et al. 2009), it has also been 
proven to be involved in the cell death of retinal photoreceptors in retinal degeneration 
models (rd1 mice, P23H andS334ter rats) (Paquet-Durand, Silva et al. 2007, Kaur, Mencl 
et al. 2011). Currently, oxidative stress is also considered to play an important role in 
hereditary retinopathy (Komeima, Rogers et al. 2007). An oxidative in particular DNA 
damage can lead to PARP activation. Excessive activation of PARP and high levels of PAR 
as a neurotoxin can lead to the cell death of neurodegenerative diseases (Yu, Kuncewicz 
et al. 2006, Vosler, Sun et al. 2009), in which PARP plays a leading role in the Caspase-
independent apoptosis.   
1.7 Treatment strategy in retinitis pigmentosa 
1.7.1 Background 
The treatment strategies of HRDs now focus on a variety of different approaches 
including stem cell transplantation, sub-retinal prosthetic devices, gene therapy, and 
neuroprotection. Each of these approaches is adequate only at a specific time-point with 
the progression of retinal degeneration. The main disadvantage of corrective gene 
therapy is its narrow applicability due to its limitation to only one gene/mutation, and 
the need to intervene as early as possible. Cell transplantation and prosthesis are 
applicable only once the degeneration has destroyed most or all of the outer retina, 
while neuroprotection is most useful at intermediate stages of HRD (Silverman and 
Hughes 1990, Lavail, Li et al. 1992, Aramant and Seiler 2004, Delyfer, Leveillard et al. 
2004, Inoue, Iriyama et al. 2007).  
1.7.2 Neuroprotection 
Neuroprotection intends to improve neuronal survival in neurodegenerative diseases by 
strengthening neuronal metabolism using neurotrophic factors such as nerve growth 
factor (NGF), and blocking or delaying neuronal cell death mechanisms, using, for 
instance anti-apoptotic compounds (Bennett, Zeng et al. 1998, Uteza, Rouillot et al. 1999, 
Liang, Allen et al. 2000). Compared to gene therapy, neuroprotection is a mutation-
independent approach that also benefits from a larger window-of opportunity, from the 
onset of HRD until almost the end of the degeneration (Trifunovic, Sahaboglu et al. 
2012). 
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1.7.3 Neuroprotection of Pde6a retinas using a specific inhibitor of PARP  
Previously, research on Pde6 mutant animals has focused on Pde6b mutants, namely the 
rd1 and rd10 mouse models (Keeler 1924, Chang, Hawes et al. 2002). In these Pde6b 
mutants the activity of Poly (ADP-ribose) polymerase (PARP) was shown to be of major 
importance for the progression of photoreceptor degeneration (Paquet-Durand, Silva et 
al. 2007, Arango-Gonzalez, Trifunovic et al. 2014). To date, Pde6a mutants have been far 
less studied and here, we used two different homozygous Pde6a mutant mice, the 
Pde6aV685M*V685M and the Pde6aR562W*R562W animals. In the human situation homozygosity 
for a mutant allele is extremely rare, however, recently a small subgroup of RP patients 
was identified that carries a compound heterozygous Pde6aV685M*R562W mutation. 
Therefore, we crossed Pde6aV685M*V685M and Pde6aR562W*R562W animals with each other to 
create a compound heterozygous Pde6aV685M*R562W RP mouse model that was genotype-
matched to human RP patients. Considering the above, Calpain and PARP activation 
played an important factor in photoreceptor degeneration of Pde6a mutants in vivo, 
therefore, targeting them by drug approaches may address a wide spectrum of RP 
mutations while working on a mutation independent neuroprotective therapeutic 
strategy. So, the aim is to investigate the efficacy of specific PARP inhibitors and explore 
the therapeutic potential in the neuroprotection of the degenerating retina by using the 
organotypic retinal culture protocol for Pde6aV685M Pde6aV685M*R562W Pde6aR562W and 
Pde6aD670G mice.   
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1.8 Aims of study 
       Nowadays, clinical patient care and the availability of integrated diagnostics for 
HRDs are not well established and most importantly, there is currently no effective cure 
available. Previous studies have shown an important role for Calpain and PARP activity 
in retinal degeneration in rd1, rd10, P23H, S334ter animal models (Sahaboglu, Tanimoto 
et al. 2010, Kaur, Mencl et al. 2011, Trifunovic, Sahaboglu et al. 2012). However, there 
are no studies about the potential involvement of PARP, PAR, Calpain and Caspase in 
Pde6a animal models for retinal degeneration.  
Hence my work focused on the following aims: 
1. Quantify photoreceptors undergoing cell death with TUNEL staining in 
Pde6aV685M, Pde6aV685M*R562W, Pde6aR562W and Pde6aD670G animal mutants in vivo 
2. Measure the photoreceptor rows in Pde6a mutants at different time points in vivo 
3. Study PARP and Calpain activity in photoreceptor degeneration in Pde6a mutants 
in vivo 
4. Evaluate the neuroprotective potential of specific inhibitors on Pde6a mutant 
retina in vitro.  
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2. Materials and methods 
2.1 Materials 
Table 2.Materials and Products 
Chemicals, Material, Devices, and 
software 
Company  Product No. 
Axio Imager Z1 Apo Tope 
Microscope 
Carl Zeiss Micro Imaging GmbH, 
Gottingen 
- 
Axio Vision 4.7 Software Carl Zeiss Micro Imaging GmbH, 
Gottingen 
- 
Caspase 3 Cell Signaling Technology, USA P42574 
Paraformaldehyde (PFA) Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany 
P 6148 
Pde6a V685M B6.A Tyr+-nmf282/J  Jackson Labs - 
Pde6a V685M*R562W Jackson Labs - 
Pde6a R562W GenOway - 
Pde6a D670G Jackson Labs  
C3H Tübingen university - 
Adobe CS5 Design Standard 
Version12.0.3*32 
Adobe systems GmbH, Munich, 
Germany 
- 
Culture Plate insert (only 
culture); 30mm Diameter, 0. 
45µm pore sizes 
Merck Millipore Ltd; Mill cell, 
Germany 
PIHA 01250 
Proteinase K Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany 
P 6556 
R16 Powder Medium (Basal) Invitrogen Life Technologies, 
Darmstadt, Germany 
07490743 
Ethanol Merck, Darmstadt, Germany ETO-500-99-
1 
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DAPI Vector, Burlingame, CA, USA D-9542 
Dithiothreitol (DTT) Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany 
43817 
O.C.TTM Compound Tissue-Tek, Leica, Bensheim, 
Germany 
1418901035 
Vectashield® DAPI Vector, Burlingame, CA, USA H-1500 
Vectashield® without DAPI  Vector, Burlingame, CA, USA H-1000 
Diaminobenzidine (DAB) Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany 
D5637 
GraphPad Software Prism 6.01 GraphPad Software, La Jolla, CA, 
USA 
- 
BSA Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany 
 
Transferrin Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany 
T-8027 
Progesterone Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany 
P-8783 
Insulin Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany 
I-6634 
T3 Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany 
T6397-
100mg 
Corticosterone Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany 
862290 
Thiamine HCI Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany 
T1270 
Vitamin B12 Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany 
V6629 
(+/-)-α-Lipoic Acid (=Thiotic 
Acid) 
Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany 
T1395 
Vitamin C Sigma-Aldrich Chemie GmbH, A4034 
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Taufkirchen, Germany 
Retinol/ Retinylacetate Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany 
R7632 
DL-Tocopherol/-acetate Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany 
T1539_25mg 
Linolic Acid/Liolenic Acid Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany 
L1012 
L-Cysteine HCI Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany 
C7477 
Glutathione Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany 
G6013 
Na-pyruvate Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany 
P3662 
Glutamine/Vitamin C Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany 
G8540 
Tris Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany 
154563 
Acetic acid EM SURE® Merck kGaA, 
Darmstadt, Germany 
K43073263 
202 
TUNEL® assay (In Situ Cell Death 
Detection Kit) 
Roche, Mannheim, Germany  1215679291
0 
ABC Kit Vector Lab, Burlingame, CA, USA H-3300 
Biotin-Block-Kit Vector Lab, Burlingame, CA, USA SP-2001 
Trizma base Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany 
T-1503 
Triton X-100 Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany 
X-100 
Magnesium chloride Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany 
M-2670 
Biotinylated NAD Trevigen 4670-5000-
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01 
HEPES Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany 
H-3375 
KCI Merck 1.04933 
MgCI2 Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany 
M-2670 
CaCI2 Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany 
C-3306 
CMAC, t-BOC-Leu-Met Molecular Probes A-6520 
 
Table 3.Antibodies used in immunohistochemistry 
Primary Antibodies: mAb, pAb, Gt: goat, Ms: mouse, Rb: Rabbit. 
Antigen Host Source/Cat.number IHC 
Actin Ms, mAb Milipore Billerica, MA,  
USA/mab1501 
1:200 
Actin Rb, pAb Abcam, UK/ab 1801 - 
Avidin-Alexa 488 - Molecular Probes, USA/ 
A-21370 
1:80 
Cleaved Caspase-3  Rb, mAb Cell Signaling, USA/9665 1:400 
PARP  Ms, mAb BD Bioscience, San Jose, CA/ 
556362 
- 
PAR (10H) Ms,mAb,IgG3 Gene Tex, CA,USA/ 
GTX75054 
1:200 
 
Media and Buffers 
0.1 M PB (Phosphate buffer) 
● Solution A.  6.89 g NaH2PO4 x H2O in 250 ml distilled ddH2O (0.2 M) 
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● Solution B. 14.19 g NaH2PO4 in 500 ml ddH2O (0,2M) 
● Add A in B to reach a pH of 7.4 
● 0.1 M PBS (Phosphate buffered saline) 
● Dilute PB stock solution in ddH2O (1:20), to have 0.01 M PB 
● Add 9 g / liter of NaCl to have 0.01 M PBS 
50 mM TBS (tris buffered saline) 
● 6 g Tris in 900 ml ddH2O 
● Adapt pH to 7.6 
● Complete until 1000 ml with ddH2O 
● Add 9 g / liter of NaCl 
4 % Paraformaldehyde (PFA) 
● 12 g PFA +150 ml PB 
● Place it in the 60℃ for 45 min 
● Add PB to dissolve until clear 
● Room temperature: Add 280ml PH 7.4 into NaOH 
● Dissolved to 300ml 
10% Sucrose 
● 20 g Sucrose dissolved in 200 ml PB 
20% Sucrose 
● 40 g Sucrose dissolved in 200 ml PB 
30% Sucrose 
● 60 g Sucrose dissolved in 200 ml PB 
Basal medium (R16) 
First, R16 powder was dissolved in 500 ddH2O and 32.5 mM NaHCO3, 30 / 60 nM 
NaSeO3 X 5H2O, 5 nM MnCl2 X 4H2O, 10 / 20 nM CuSO4 X 5H2O and 1 ml of 1 µg / ml 
Ethanolamine and 0.1 µg / ml Biotin were added in the same solution and filled up to a 
volume of 800 ml. Then the mixture was filtered and aliquoted into a volume of 50 ml. 
  
34 
 
Complete medium (Amount for 50 ml) 
0.2% BSA, 50 µl Transferrin, 50 µl Progesterone, 50 µl Insulin, 50 µl T3, 50 µl 
Corticosterone, 50 µl Thiamine HC1, 50 µl Vitamin B12, 100 µl (+/-)-a-Lipoic Acid 
(=Thiotic Acid), 50 µl Retinol / Retinylacetate, 100 µl DL-Tocopherol / -acetate, 100 µl 
Linolic Acid/Linoleic Acid, 50 µl L-Cysteine HC1, 50 µl Glutathione, 50 µl Na-pyruvate, 
0.5 ml Glutamine / Vitamin C, 6.15 ml ddH2O were added into 40 ml Basal R16 Medium.  
Proteinase K 
To dissolve 250 mg Proteinase K Powder into 2.5 ml ddH2O. Afterwards, dissolve 2.4 ml 
Proteinase K in 200 ml Basal medium and prepare 2 ml aliquot to for later use.  
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2.2 Methods 
2.2.1 Animal procedures 
All Pde6a mutants used were of the C57BI6 / J strain. The Pde6aV685M and Pde6aD670G 
mice were obtained from the Jackson Labs (Bar Harbor, MA, USA). The Pde6aR562W mice 
were generated by GenOway (Lyon, France). Pde6aV685*R562W compound heterozygous 
mice were generated at the University of Tübingen. All procedures were approved by 
the Tübingen University committee on animal protection and performed in compliance 
with the ARVO statement for the use of animals in Ophthalmic and Visual Research. 
Protocols compliant with the German law on animal protection were reviewed and 
approved by the ‘‘Einrichtung fur Tierschutz, Tierarztlichen Dienst und 
Labortierkunde’’. All efforts were made to minimize the number of animals used and 
their suffering. 
 
 
Figure 8.Retinal explants cultures 
Retinas from Pde6a mutants were cultured at P25, P19, and P15 respectively. Before 
being treated with PJ34, the explants were allowed to adjust to in-vitro culturing 
conditions for 2 days. The cultures got treatments from P9 to P25-P19 and P15 
respectively. Complete Medium without PARP inhibitor was used as the control. 
 Retinal explant culture procedure 
All Pde6a animals for culturing were decapitated at postnatal day 5. After cleaning the 
heads with 70% ethanol, the eyes were removed under aseptic conditions, and placed 
into the Basal Medium for washing for 5 minutes followed by a 8-10 minute incubation 
in 0.12% Proteinase Kat 37℃ in order to inactivate the enzyme action by protein 
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dilution. After this step the eyes were placed in Basal Medium with 10% FCS (Fetal Calf 
Serum) for 2 minutes to deactivate the Proteinase K. The eyes were placed in Basal 
Medium during the whole procedure. The anterior segment, lens and vitreous body 
were removed from the eyeballs carefully. The optic nerve was then cut. Afterwards, the 
retinas were removed from sclera together with the attached retinal pigment 
epithelium. Then the retinas were cut into four wedge shapes. Afterwards the retinas 
were transferred to a 0.45 µm Cell culture Plate inserts (Mill cell, Cell Culture Inserts, 
30mm Diameter, Merck Millipore Ltd. Tüllagreen, Germany), and were butterflied open 
with the ganglion cell layer facing up. Subsequently, the membrane was placed in a six 
well culture plate (Falcon, BD Biosciences, and San Jose, CA, USA) and incubated in 1.3 
ml of Complete Medium at 37 ℃ in an incubator with humidity and 5% CO2. All steps 
were done under the microscope and under sterile conditions.  
2.2.2 Tissue Preparation (Embedding and section) 
Prepare before 
● 70% Ethanol 
● 4% Paraformaldehyde (PFA) 
● PBS (0.1 M; PH7.4) 
● Sucrose (10%, 20%, 30%) 
● Liquid nitrogen (Liquid N2) 
● Compound embedding (Tissue-Tek) 
 
Procedure  
Pde6a mice (P9-P35) mice were sedated with CO2 and then decapitated. The heads were 
cleaned with 70% Ethanol, and the eye was removed.  Subsequently, the eyes were 
punctured at the nasal part of the eye and incubated in 4 % PFA for 45 minutes at room 
temperature (RT).  After washing in PBS (0.1M; PH 7.4), the cornea was cut along the 
limbus, then the Cornea, Lens, and vitreous were removed, and put in 4% PFA for 45 
minutes at RT.  After washing in PBS 3 times for 10 minutes, the eyecups were kept for 
10 minutes in 10% sucrose, 20 minutes in 20% sucrose and 30 minutes in 30% sucrose 
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at room temperature. After cryo-protection, the tissues were embedded in O.C.TTM 
compound (Tissue-Tek, Leica, Bensheim, Germany), and immediately frozen in liquid 
nitrogen and then stored at -20℃ until sectioning. For unfixed tissues, the eyes were 
quickly and directly frozen in liquid nitrogen followed by embedding in O.C.TTM 
cryomatrix, and then stored in the -20℃. 
2.2.3 Dissection of retina 
Prepare before 
● 70% Ethos 
● 4% Paraformaldehyde (PFA) 
● PBS (0.1 M; PH 7.4) 
● Sucrose (10%, 20%, 30%) 
● Liquid nitrogen (Liquid N2) 
● Compound (Tissue-Tek) 
Procedure 
The eyes were enucleated and fixed in 4% PFA for 45 minutes. Subsequently, the retinae 
were washed in PBS (0.1 M, PH 7.4) for 5 minutes. Then cryo-protection was performed 
by submergence in 10% sucrose for 10 minutes, 20% sucrose for 20 minutes, and 30% 
for 30 minutes. Afterwards, the retinae were embedded in O.C.TTM compound (Tissue-
Tek, Leica, Bensheim, Germany) and were stored at -20℃. The retinae blocks were 
sectioned sagittally with 14 µm thicknesses by using a microtome (Leica RM 2155, 
Nussloch, Germany) and then the slides were stored at -20℃ for further experiments. 
 
2.2.4 TUNEL (In Situ Cell Death Detection Kit) assay 
The TUNEL assay is a common method for detecting DNA fragmentation which is one of 
the last steps of cell death. Because of the presence of a fluorescein, nucleotide polymers 
can be detected and quantified by fluorescence microscopy (Gavrieli, Sherman et al. 
1992).  
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Prepare before 
● Proteinase-K Dilution 
Proteinase-K  1× 2× 3× 
0.05M Tris PH 7.6 42 ml 84 ml 100 ml 
Proteinase-K 6 µl 12 µl 14.3 µl 
● Ethanol-Acetic Acid-Mix 
70% Ethanol  49 parts 
30% C2H4O2    9 parts 
H2O    21 parts 
● Blocking solution 
10% NGS  
1% BSA 
1% fish gelatin  
0.003% PBST 
● TUNEL-Kit 
Solution Components For 100 µl 
Enzyme (blue) Terminal deoxynucleotidyl transferase 
(TdT) from calf thymus, recombinant in E. 
coli  
6.25 µl 
Label (Lila) Nucleotide mixture in reaction buffer 56.25 µl 
Blocking solution See above 62.50 µl 
 
Procedure 
Fixed slides were dried at 37℃ for 40 minutes, and were washed in PBS at room 
temperature for 15 minutes. Afterwards, the slides were placed in Tris + Proteinase K at 
37℃ for 5 minutes to inactive nucleases, which may reduce the nucleic acids. Then the 
slides were washed with Tris (10 μg / ml in 10 mM TRIS-HCL, pH 7. 4 – 8. 0) 3 for 5 
minutes. Subsequently, the slices were placed in Ethos-Acetic Acid-Mix at -20℃ for 5 
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minutes and then blocked with blocking solution for 1 h at room temperature. Lastly, the 
slides were placed in the TUNEL kit (Fluorescein or TMR; Roche Diagnostics GmbH, 
Mannheim, Germany) in 37 ℃ for 1h and covered with Vectashield with DAPI (Vector, 
Burlingame, CA, USA) thereafter.          
2.2.5 Caspase 3 immunostaining 
For immunofluorescence analysis, retinae sections were rinsed in PBS and incubated in 
blocking solution (10% normal goat serum, 1% bovine serum albumin, and 0.1% Triton 
X in PBS) for 1hour at room temperature. Sections were incubated with an antibody 
directed against cleaved activated Caspase-3 (1:400, Cell Signalling Technology, USA; 
Orders. 877-616-CELL 2355), which was diluted in blocking solution overnight at 4℃. 
Subsequently, sections were washed in PBS and mounted in Vectashield with DAPI 
(Vector, Burlingame, CA, USA). 
2.2.6 Calpain activity Assay 
Calpain is a type of Ca2+ activated protease which activate when the levels of Ca2+ 
increase (Azarian, Schlamp et al. 1993). The permeable fluorescent Calpain substrate, 
tert-butoxycarbonyl-L-leucyl-Lmethionineamide-7-amino-4-chloromethylcoumarin 
(Boc-Leu-Met-CMAC), was used to assess Calpain activity at the cellular level in 
photoreceptors of Pde6a mutants.     
Prepare before 
● Calpain Reaction mix 
Volume Stock  Working concentration 
1000 µl Ready to use (HEPES 25 
mM 5.96 g; KCL 65 mM 
4.85 g,CaCl2 15 mM 0.22 g, 
2 mM MgCl2, 60 ml ddH2O) 
10 × 
Reaction buffer 
(CRB 1×) 
Adjust PH to 7.2 and 
complete the volume to 
100 ml with ddH2O 
2 µl 1 mM DTT 1 µl 
5 µl 10 µM CMAC 5 µl 
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Procedure 
Unfixed retinal slides were dried at room temperature for 10 minutes and then washed 
with CRB for 15 minutes. Thereafter, the 1×CRB+CRM (Calpain reaction mix) was added 
to the slides and incubated for 2 h in the 37℃ incubator. Lastly, the slides were washed 
with 1 × CRB for 2 × 10 minutes and kept in the dark. Finally, the slides were covered 
with Vectashield without DAPI (Vector, Burlingame, CA, USA). 
2.2.7 Poly ADP ribose polymerase In-situ Enzyme activity Assay (PARP) 
Prepare before 
● TB 100 mM, PH8.0 
● 12.14 g Trizma base dissolve in 600 ml ddH2O 
● PH 8.0 With 2NHCL 
● Fill to 1000 ml with ddH2O 
● PARP reaction buffer (PRB)  
● TB, 0.2%Triton, 10 mM MgCL2 
● 250 ml Trisma Base 
● 500 µl Triton * 100 
● 0.508 g MgCL2 dissolve 
● Heat the oven to 37℃ 
● Set the PARP reaction mix Dithiothreitol (DTT) Stock solution, 1 M 
● 154.25 mg dissolve in 1 ml ddH2O 
PARP reaction mix 
Name Stock solution Working 
concentration 
Volume 
Reaction buffer 
(RB) 
100 mM TB PH 8.0 0.2%Triton, 
10 mM MgCl2 
- 980 µl 
DTT 1 M 1 mM 1 µl 
Biotinylated NAD 250 µM 5 µM 20 µl 
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Procedure 
The unfixed retinae tissue were air-dried at room temperature for 10 minutes and 
subsequently washed in TB (Tris base buffer 100 mM PH 8.0; 4℃) for 10 minutes. 
Afterwards, the slides were placed in cover-plates and washed with a 1 × TB buffer. 
Subsequently, Avidin Block was placed on each slide (3 drops / slide) and left for 15 
minutes. Thereafter, washing with TB 2 × 5 minutes followed this step.  Again, a few 
drops were added of Biotin Block to each slide (3 drops / slide) for 15 minutes. The 
slides were washed with TB 2 placed on each slide (3 drops / slide) and left for 15 
minutes. Afterwards, a PARP reaction mix was applied in 37℃ for 2.5 h, and later 
washed with PBS 3 x 5 min. For detection of incorporated biotin, Alexa 488, Avidin 
1:800 in PBS was applied for 1 hour and followed by washing in PBS. Lastly, the slides 
were covered with Vectashield with DAPI (Vector, Burlingame, CA, USA). 
2.2.8 Poly (ADP-ribose) (PAR) immunohistochemistry 
 
Prepare before 
● PAR Quenching 
Name Working concentration  Volume 
PBST  1: 1000 500 µl 
MeOH 400 µl 70% 400 µl 
H2O2 (Hydrogen peroxide) 30 : 100 100 µl 
● Blocking solution 
Stock solution Working concentration Volume 
PBST 1: 1000  1000 µl  
NGS 1: 10 100 µl 
● Prepare PAR-Primary antibody  
Name Source Dilution Working concentration 
PAR (10H) Enzo / ALX-804-220, 
Ms, mAb 
1 : 200    4 µl 
42 
 
● Prepare PAR-secondary antibody  
Name Source  Dilution Working concentration 
Biotinylated 
lgG (H+L) 
Vector Laboratories, 
CA, USA, Gt anti Ms 
1 : 150 6 µl 
●  Prepare ABC kit 
Name Information Source  Dilution Working 
concentration 
Avidine Gt anti Ms Vector Laboratories, CA, 
USA 
1 : 150 1 µl 
Biotin  Vector Laboratories, CA, 
USA 
 1 µl 
 
Procedure         
For this immunohistochemistry assay, the fixed cryo-sections were dried at 37 ºC for 1 
h, and then washed with PBS for 10 min at room temperature. To reduce non-specific 
background, quenching solution (100 µl 30% H2O2, 400 µl Methanol 500 µl PBST) was 
placed in each section for 20 min at room temperature. Then, blocking solution (10% 
NGS, 0.1% PBST) blocked the slices for 1 h at room temperature. Thereafter, the slides 
were incubated with primary antibody (PAR 10 H, lgG3 Alex3 1 : 200) at 4℃ overnight. 
After that, the slides were washed with PBS 3 times for 10 min, and then were incubated 
with the second antibody (Biotinylated goat anti mouse, 1 : 150) at room temperature 
for 1 h. After the washing step, slides were incubated in Vectastain Elite ABC kit (Vector 
lab) for 1 h at room temperature. The slides were placed in a solution which included 40 
mg 3, 3’-diaminobenzidine (DAB), 20% Glucose, 0.4% Nickel ammonium sulphate, 40 µl 
Glucose oxidase and incubated for 3 min for the colour reaction.  After they were washed 
by PB 3 times for 10 min. Slides were covered with by Aquatex (Merck).  
2.2.9 Microscopy, cell counting, and statistical analysis 
Light and fluorescence microscopy were performed with a Z1 Apo Tome Microscope 
equipped with a Zeiss Axiocam digital camera. Images were captured using Zeiss 
Axiovision 4.7 software and representative pictures were taken from central areas of the 
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retina. Adobe Photoshop CS3 (Adobe Systems Incorporated, San Jose, CA) and Corel 
Draw X3 software was used for primary image processing. For cell quantifications, 
pictures were captured of whole radial slices using the Mosaix mode of Axiovision 4.7. 
Labelled cells were counted manually. The total number of cells was determined by 
dividing the outer nuclear layer (ONL) area through the average cell size. The total 
number of ONL cells was determined by taking the percentage of positive cells then 
dividing the number of positive cells. All data given represent the means and standard 
deviation from three sections each, for at least three different animals. Statistical 
comparisons between experimental groups were made using one-way ANOVA and 
Bonferroni’s correction using Prism 5 for Windows (Graph Pad Software, La Jolla, CA). 
Values are given as mean ± standard deviation (SD) or standard error of means (SEM). 
Levels of significance were as follows: n.s., p > 0.05; *, p < 0.05; **, p < 0.01; ***, p < 
0.001. 
  
44 
 
3. Results   
 
3.1 Characterization of four Pde6a mutants in vivo 
3.1.1 The peak of photoreceptor cell death in different Pde6a mutants in vivo 
Programed cell death relates to the orderly process of changes in cell morphology and 
biochemistry that finally results in cell death (Kerr, Wyllie et al. 1972). A variety of 
programmed cell death mechanisms are known, including apoptosis, programmed 
necrosis, necroptosis, and PARthanatos (Leist and Jaattela 2001). TUNEL (Terminal 
deoxynucleotidyl transferees dUTP nick end labeling) is a common method to detect 
DNA fragmentation as end result of apoptosis but also of other forms of cell death, for 
instance in necrosis (Loo 2002). We used the TUNEL cell death assay to identify 
photoreceptor cell death in different models for Pde6a mutation, and we found that cell 
death starts at P9 in Pde6aV685M, Pde6aV685M*R562W, and Pde6aR562W and at P14 in 
Pde6aD670G. Thus, TUNEL staining showed retinal photoreceptor cell death in early stages 
and it was significantly elevated from P9 onwards in 4 different Pde6a animal models.  
Overall, TUNEL positive cells were identified as late as PN30 in four Pde6a mutants. In 
wild type wt (C3H) controls, TUNEL positive cells were seen only occasionally in the 
ONL at this age (Figure 9). Compared to wt retinae, Pde6aV685M retinae showed a 
significant elevation of photoreceptor cell death at PN12 (Table 3).  The photoreceptor 
degeneration in the Pde6aV685M mutant was the earliest compared to other Pde6a 
mutants. The TUNEL positive cells peaked at PN12 in Pde6aV685M while in Pde6aD670G the 
TUNEL peak was at PN21. In other Pde6a mutants, TUNEL-positive cells peaked at PN15 
for Pde6aR562W and Pde6aV685M*R562W and all Pde6a mutants showed significantly higher 
numbers of TUNEL positive cells than wild type animals (Figure 9). 
In these Pde6a models, photoreceptor rows showed the highest number at PN9 (11 ONL 
cell rows remaining), declining thereafter. Dying cells and photoreceptor cell rows were 
quantified until PN35 (Table 3, Figure 9). 
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Figure 9. TUNEL assay and cell death in Pde6a mutants 
The number of TUNEL positive cells in the 4 different Pde6a mutants ONL was strongly 
increased when compared with wt (A-E). Quantification of photoreceptor cell death and 
photoreceptor rows during the first 35 postnatal days (F, G). Increased numbers of 
TUNEL positive cells, showing a peak at PN12 in Pde6aV685M, PN15 in Pde6aR562W, PN15 in 
Pde6aV685M*R562W and PN21 in Pde6aD670G was observed (F). Quantification of 
photoreceptor rows during the first postnatal month. In Pde6aV685M, photoreceptor rows 
showed the highest number at PN9 (11 ONL cell rows remaining), declining thereafter. 
In the other three mutants the photoreceptor rows showed the highest number at PN11 
(11 ONL cell rows remaining), declining thereafter. In the Pde6a models, dying cells and 
photoreceptor cells rows were detectable as late at PN35 (G). The values shown 
originate from four Pde6a mutants from at least three different specimens. Scale bar 
represents 20 µm. 
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3.1.2 Cell death in Pde6a mutants 
Caspase-3 is a critical executioner of apoptosis, as it is either partially or totally 
responsible for the proteolytic cleavage of many key proteins, such as the nuclear 
enzyme poly (ADP-ribose) polymerase (PARP)(Casao, Mata-Campuzano et al. 2015). 
Since photoreceptor cell death in retinal regenerations is frequently defined as 
apoptosis; the detection of activated Caspase-3 by an antibody that is specific to the 
activated form of Caspase-3 was used to analyze real involvement of apoptotic 
photoreceptor cell death in Pde6a mutants. However, only a few cells with activated 
Caspase-3 were seen in ONL of each Pde6a model, and there were no significant 
difference between the controls and the Pde6a mutants (Table 3, Figue10), indicating 
that the staining only correspond to developmental cell death. Thus, we discarded 
apoptosis as the main cell death pathway in these mutants.   
3.1.3 Calpain activity is increased in Pde6a mutants and wild type retina in vivo 
The activation of Ca2+-dependent protease Calpain has been implicated in retinal 
neurodegeneration, and it is usually associated with alternative cell death mechanisms 
(Paquet-Durand, Azadi et al. 2006, Paquet-Durand, Sanges et al. 2010). Photoreceptor 
degeneration in most mutations of RP often affects rods first and then cones through an 
unknown cell death pathway (Delyfer, Leveillard et al. 2004). The localization of Calpain 
activity is of major importance both for our understanding of the degenerative 
mechanisms and the assessment of potential neuroprotective treatments (Paquet-
Durand, Johnson et al. 2007). 
So far, still no publications have addressed the role of Calpain activity in retinal 
degeneration of a Pde6a mutant. Here we reported four different Pde6a animal models. 
In the Pde6a mutants, numerous photoreceptors in the ONL were nicely labeled with our 
assay for Calpain activity, but in wild-type animals very few positive cells were 
observed. The numbers of cells showing Calpain activity in Pde6aV685M ONL were higher 
at various postnatal ages as compared to the wild type. Calpain activity was increased 
early at P9 and peaked at P12 (Table 3). The Pde6aV685M*R562W retinae showed 
comparatively higher number of cells with activated Calpain when compared to the wild 
type; the peak of the Calpain positive cells was at P15 (Table 3). Calpain activity in 
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Pde6aR562W appeared as early as at P11, the number of Calpain positive cells peaked at 
P15 (Table 3).  In the Pde6aD670G mutant, the increase of Calpain activity was found at 
P14 and showed statistical significance at P18, and peaked at P21 (Table 3) with a later 
decrease at P24 (Figure10). 
 
Figure 10.Activation of Calpain and Caspase-3 assay in Pde6a mutants  
Photoreceptor degeneration in Pde6a mutants correlates with Calpain activity, however   
activation of Caspase-3 was not detected in these animals. Immunofluorescence for 
activated Caspase-3 reveals no major differences between wild-type and mutant retinae 
(A-E). This is also illustrated by the quantification of Caspase-3 positive cells, which 
shows low numbers of positive cells at the respective peaks of degeneration (K).  In 
contrast, the in situ Calpain activity assay reveals strong differences between wild-type 
(F) and all four Pde6a mutant situations (G-J). The progression of Calpain activity was 
analyzed over time (L, M) and shows a strong correlation to the retinal degeneration. 
The values shown originate from four Pde6a mutants from at least three different 
specimens. Scale bar represents 50 µm. 
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3.1.4 PARP activity in Pde6a mutants in vivo 
In order to investigate the involvement of PARP as a latent photoreceptor cell death 
marker in these Pde6a mutants, we studied the expression and activation of PARP. This 
may allow us to identify opportunities for treatment of RP patients in the future. PARP 
activity at the cellular level was detected utilizing an in-situ enzyme activity assay that 
detects the incorporation of biotin labeled NAD+ (Paquet-Durand, Silva et al. 2007). 
In wild-type retinae, very little PARP activity was detected. In comparison to wt, PARP 
activity in Pde6aV685M peaked at P12. And in Pde6aV685M*R562W, Pde6aR562W and Pde6aD670G   
PARP activity showed a peak at P13, P15 and P21 respectively and the number of PARP 
positive cells was significantly different than wt (Table 3,Figure 11,12).   
3.1.5 PARylated proteins in Pde6a mutants in vivo 
We quantified the amount of PARylated protein in the four Pde6a mutants. The 
quantification of PARylated protein showed increased poly(ADP)-ribosylation of 
proteins in each Pde6a mutant’s photoreceptors. In comparison to wt, the statistical 
analysis of PAR positive cells showed significant differences for Pde6aV685M at P12, 
Pde6aV685M*R562W at P15, Pde6aR562W at P15, Pde6aD670G at P21 (Table 3) (Figure 11P-T, 
12F).     
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Figure 11. Differential regulation of markers linked to cell death in Pde6a mutants 
The presence of DNA nick-ends and the presence and activity of the three enzymes 
Caspase-3, Calpain, and PARP, linked to cell death were analyzed.  Shown here are: 
TUNEL assay for cell death (A-E) Presence of activated Caspase-3 for apoptotic cell 
death (F-J), in situ Calpain activity assay for non-apoptotic cell death (K-O), PARylated 
protein immunohistochemistry for non-apoptotic cell death (P-T), and in situ PARP 
activity assay for non-apoptotic cell death (U-Y). Although there was no significant 
difference between wt and Pde6a mutants for the presence of Caspase-3, there were 
significant differences between wt and Pde6a mutants for nick-ends in the DNA (i.e. cell 
death), Calpain activity, the presence of PARylated protein and the activity of PARP. 
Scale bar = 20 µm.  
51 
 
 
 
 
52 
 
 
Figure 12. PARP activity and PARylation accumulation in different Pde6a mutants 
The number of TUNEL-positive cells in the Pde6aV685M, Pde6aV685M*R562W, Pde6aR562W and 
Pde6aD670G photoreceptors was significantly increased when compared with wt (A-E). 
Progression of photoreceptor cell death in Pde6aV685M, Pde6aR562W, Pde6aV685M*R562W and 
Pde6aD670G showed a peak at P12, P15, P15 and P21 respectively. However, only a few 
Caspase-3 positive cells were seen in ONL of each Pde6a animal models, and there were 
no significant differences between wt and Pde6a mutants (F). PAR accumulation as 
secondary evidence of PARP activity was found in large amounts in ONL of each of the 
Pde6a mutants (G). The number of PARP activity-positive cells in Pde6a mutants was 
strongly increased when compared with wt (K-H). Progression of PARP activity at 
different time points showed a peak at P12, P13, P15, P21 for Pde6aV685M, 
Pde6aV685M*R562W, Pde6aR562W and Pde6aD670G respectively (A, B, C, D, H). The images 
shown are representative for observations on at least three different specimens for each 
genotype. *P<0.05.Scale bar = 20 µm.  
3.1.6 Summary of characterization of Pde6a mutants in vivo 
Our detailed characterization of different homozygous and compound heterozygous 
mouse models for RP provide not just a better view of the mechanisms of RP 
degeneration, but will also provide a base for investigations, in particular for the 
determination of the best possible time-frame for therapeutic interventions in the 
future. 
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Table 4.Characterization of Pde6a mutants in vivo 
Animal n TUNEL Caspase- 3 Calpain PARP PAR Phot. rows 
wt 6 0.07 ± 0.02 0.10 ± 0.01 0.08 ± 0.01 0.08 ± 0.02 0.11 ± 0.01 11.24 ± 0.48 
V685M  
6 
7.09 ± 0.14 
(***) 
0.09 ± 0.01 
(ns) 
2.80 ± 0.45 
(***) 
1.36 ± 0.17 
(***) 
1.02 ± 0.07 
(***) 
3.90 ± 0.61 
(***) 
V685M* 
R562W 
 
6 
4.05 ± 0.10  
(***) 
0.10 ± 0.01 
(ns) 
2.46 ± 0.46 
(**) 
1.43 ± 0.08 § 
(***) 
1.92 ± 0.23 
(**) 
5.67 ± 0.24 
(***) 
R562W  
6 
3.11 ± 0.74  
(**) 
0.15 ± 0.03 
(ns) 
2.66 ± 0.45 
(**) 
2.01 ± 0.40 
(**) 
1.80 ± 0.23 
(***) 
8.98 ± 0.16 
(**) 
D670G  
6 
2.17 ± 0.09  
(***) 
0.11 ± 0.01 
(ns) 
2.58 ± 0.43 
(***) 
2.17 ± 0.47 
(**) 
0.87 ± 0.28 
(*) 
6.09 ± 0.32 
(***) 
 
Summary of assay results in the four different Pde6a mutants in vivo, at the respective 
peak of cell death.  (V685M at P12, V685M*R562W at P15, R562W at P15 and D670G at 
P21, always vs. wt P15 condition). TUNEL, Caspase-3, Calpain, PARP, PAR, Photoreceptor 
rows levels of significance were as follows: n.s.=p>0.05; *=p<0.05; **=p<0.01; 
***=p<0.001.  Parameters are presented as mean ± standard deviation (S.D).  
§=Postnatal 13. 
3.2. Treatment of Pde6a mutants in vitro  
3.2.1 PARP inhibition delays photoreceptor cell death in Pde6a mutants in vitro  
Our in vivo study showed that the cells positive for assays of TUNEL and PARP activity in 
the ONL of Pde6a mutants were strongly increased when compared with wt in vivo. In 
addition, in our previous study, 6 µm PJ34 treatments showed neuroprotective effect for 
rd1 photoreceptor degeneration (Paquet-Durand, Silva et al. 2007). In addition we used 
several concentrations of PJ34 for photoreceptor degeneration in the rd2 slow 
degeneration model. We observed a neuroprotective effect of PJ34 for 1.5 µm and 6 µm 
PJ34 treatments (unpublished data). Furthermore, it was shown that adult PARP1 KO 
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mice retinae indicated normal structural and functional behavior (Sahaboglu, Tanimoto 
et al. 2010). This suggests that inhibition of PARP1 does not have a negative effect on 
retinal development and function. So, we hypothesized that PARP inhibition could 
decrease or delay photoreceptor cell death and increase photoreceptor survival in Pde6a 
mutants in vitro. 
We used organotypic retinal cultures as an in vitro system to test our hypothesis. 
Retinae from Pde6a mutants were cultured and treated with PJ34. To assess the effective 
neuroprotection period of PJ34, we used long and short-term retinal culture periods 
using 6µM PJ34 as a treatment. First, long-term culture period (P5-P25) was used to 
analyze the neuroprotective effect of PARP inhibition on Pde6aV685M, Pde6aV685M*R562W 
and Pde6aD670G retinae for 16 days. The results from treated groups showed hardly any 
photoreceptors in these Pde6a mutants in both treated and untreated groups, which 
lead us to believe they may have been degenerated already at such a stage. Therefore the 
quantification was impossible at P25 (Data not shown) (Figure 14). When culture 
protocol was shortened from P25 to P19, we observed a single layer of photoreceptors, 
and therefore, quantification was also not possible (Data not shown) (Figure 14). There 
was a significant difference between treated and untreated groups when cultures were 
finished at P15 (Figure 13). The number of photoreceptor rows in each Pde6a mutant 
was higher after treatment while there was only one layer of photoreceptor rows in the 
untreated group (Figure 14A-U).  
We used the TUNEL assay to identify photoreceptor cell death for PJ34-treated and 
untreated Pde6a mutants. All Pde6a mutants demonstrated higher a number of TUNEL-
positive cells in the untreated groups when compared to treated groups. PARP inhibition 
by PJ34 significantly decreased the number of photoreceptor cell deaths in Pde6aV685M, 
Pde6aR562W and Pde6aV685M*R562W (Table 4, Figure 13). 
3.2.2 PARP inhibition positively affected photoreceptor survival in Pde6a mutants in 
vitro  
Short-term cultures were performed using P5 mice. The retinal cultures derived from 
Pde6a mutants were left for 4 days in regular R16 culture medium to adapt to the 
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culture situation. Every second day the culture medium was changed. Treatment with 
6µM PJ34 was started at P9 for 6 days up to a total age of P15. PJ34 treatment revealed a 
significant increase in the number of surviving photoreceptors in treated 
Pde6aV685M*R562W and Pde6aR562W (Table 4), but there was no significant difference 
between treated and untreated Pde6aV685M retinae (Table 4, Figure 13).  
  
Figure 13. PARP inhibition in short-term cultures of Pde6a mutants 
In short-term (P5-P15) cultures the number of TUNEL-positive cells in the Pde6aV685M, 
Pde6aV685M*R562W, Pde6aR562W, Pde6aD670G and wt ONL (A, E, L, M, R) was significantly 
decreased by PJ34 treatment (C, G, K, O, T), suggesting a protective effect of the PARP 
inhibitor. Treatment with PJ34 (P9-P15) resulted in a significant increase in the number 
of photoreceptor rows in Pde6aV685M/R562W Pde6aR562W and Pde6aD670G (J, N, L, P, U), but 
not in Pde6aV685M and wt (B, F, D, H) when compared with untreated specimens; the 
staining were representative of six specimens; *P<0.05. Scale bar represents 20 um. 
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Figure 14. PARP inhibition in long-term cultures of Pde6a mutants 
Long-term culture period (P5-P25) was used to analyze the neuroprotective effects of 
PARP inhibition on Pde6aR562W, Pde6aV685M and Pde6aV685M*R562W retina for 16 days.  The 
results from treated groups showed very few photoreceptors in all the Pde6a mutants in 
both treated and untreated groups and therefore the quantification was impossible at 
P25 (A, B, E, F, I, J, M, N). However, when culture protocol was optimized from P25 to 
P19, we observed only a single layer of photoreceptors, and therefore, quantification 
was not possible (C, D, G, H, K, L, O, P).  The staining was representative of at least three 
specimens. Scale bar represents 20 µm.  
3.2.3 PARP inhibition decreases Pde6a mutant PAR-positive cells in vitro 
As PARP activity generates PAR polymers, staining for PAR polymers was performed in 
retinal tissues to indirectly confirm PARP activity. PAR polymer staining showed 
numerous cells with PAR polymers in the ONL of all Pde6a mutants. Our study showed 
57 
 
that the PARP inhibitor PJ34 could decrease the number of PAR polymers in the cells of 
the ONL of Pde6a mutants in vitro (Table 4, Figure 15).  
 
 
Figure 15. PARP inhibition decreases the number of PAR polymers in cells in the 
ONL in the different Pde6a mutants 
PARP inhibition by PJ34 decreases the number of PAR positive cell in the Pde6aV685M, 
Pde6aR562W, Pde6aV685M*R562W and Pde6aD670G photoreceptors in short-term retinal 
cultures (P5–P15) (B, E, and K, N). In short-term cultures, the number of PAR positive 
cells in the wt, Pde6aV685M, Pde6aV685M*R562W, Pde6aR562W and Pde6aD670G ONL (A, D, E, J, M) 
were significant decreased by PJ34 treatment (C, F, L, O), although there was no 
significant difference in Pde6aV685M*R562W when compared with untreated specimens. The 
staining was representative of six specimens; *P<0.05. Scale bar represents 20 um.  
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3.2.4 Summary of treatment results on four Pde6a mutants in vitro 
Our preliminary results from these Pde6a mutants indicate that treatment of PARP 
inhibition by PJ34 therapy can be effective, and may have large implications in the future 
treatment of RP patients. 
Table 5.Treatment of four Pde6a mutants in vitro 
Animal n TUNEL  PAR Phot. rows 
wt 
Untreated 
Treated 
 
 
6 
 
1.23 ± 0.14 
0.42 ± 0.12 (***) 
 
 
0.12 ± 0.02 
0.04 ± 0.02 (*) 
 
 
5.89 ± 0.24 
6.36 ± 0.44 (ns) 
 
V685M 
Untreated 
Treated 
 
 
6 
 
5.84 ± 1.08 
1.95 ± 0.11 (*) 
 
 
0.39 ± 0.10 
0.13 ± 0.06 (*) 
 
 
2.92 ± 0.17 
2.33 ± 0.25 (ns) 
 
V685M*R562W 
Untreated 
Treated 
 
 
6 
 
4.11 ± 0.60 
1.76 ± 0.11 (*) 
 
0.29 ± 0.10 
0.17 ± 0.09 (ns) 
 
 
2.76 ± 0.15 
3.50 ± 0.23 (*) 
R562W 
Untreated 
Treated 
 
 
6 
 
12.58 ± 2.46 
4.63 ± 0.97 (**) 
  
1.25 ± 0.09 
0.22 ± 0.03 (***) 
 
3.44 ± 0.22 
5.40 ± 0.25 (**) 
D670G 
Untreated 
Treated 
 
 
6 
 
9.64 ± 2.69 
2.65 ± 0.62 (**) 
 
0.70 ± 0.06 
0.21 ± 0.10 (**) 
 
3.76 ± 0.20 
4.69 ± 0.18 (**) 
 
Summary of assay results between treated and untreated in the four different Pde6a 
mutants in vitro, at the post-natal day 15. TUNEL, PAR, Photoreceptor rows levels of 
significance were as follows: n.s.=p>0.05; *=p<0.05; **=p<0.01; ***=p<0.001.  
Parameters are presented as mean ± standard deviation (S.D). 
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4. Discussion 
The development of new therapies for RP and related hereditary retinal degenerations 
is still hampered by a lack of understanding of the underlying pathogenic mechanisms. 
As it is difficult to obtain Human diseased retinal tissue, the exploration into the 
pathogenesis of such diseases still relies on animal models. In this study, we present one 
of the first studies on a compound heterozygous animal model for RP. This new animal 
model (Pde6a R562W*V685M) is exactly homologous to a human RP patient genotype and 
represents one of the first ever attempts to create a patient matched animal model for 
the development and assessment of individualized RP therapies. 
    
4.1 Hereditary retinal degeneration and photoreceptor cell death 
Inherited retinal degeneration and loss of photoreceptors may be caused by genetic 
mutations in a large variety of genes (Chizzolini, Galan et al. 2011). In much of the older 
literature apoptosis has been suggested as the key mechanism driving photoreceptor 
degeneration in RP (Travis 1998). However, in recent years it has become increasingly 
clear that in fact a variety of different neurodegenerative mechanisms are involved in 
photoreceptor loss (Lohr, Kuntchithapautham et al. 2006, Arango-Gonzalez, Trifunovic 
et al. 2014). To identify suitable targets for the development of RP therapies it is 
therefore important to reach a thorough understanding about the causal degenerative 
mechanisms (Sancho-Pelluz, Arango-Gonzalez et al. 2008). In rd1 mouse retina a Pde6b 
mutation causes a loss of Pde6 function and consequently a rise in intracellular cGMP, 
eventually leading to retinal photoreceptor cell death (Farber and Lolley 1974). High 
cGMP levels will result in a direct stimulation of CNG channels, allowing for an increased 
influx of Ca2+ that is thought to trigger cell death (Paquet-Durand, Beck et al. 2011). The 
TUNEL assay is a common method for detecting DNA fragmentation that is the end-
result of cell death. In this research, TUNEL positive cell were first detected in the retinal 
photoreceptor cell layer of Pde6a mutant mice at the postnatal day 9. The number of 
positive cells obviously increased along with the time of retinal degeneration. A high 
overlap of Ca2+-activated Calpain protease activity with TUNEL in rd1 mice suggests that 
activation of Calpain causes cell death. However, Calpain activity may precede TUNEL, 
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which thus suggests that Calpain activity may be involved in earlier events during retinal 
photoreceptor cell death (Paquet-Durand, Johnson et al. 2007). Similarly, PARP activity 
is strongly elevated in rd1 photoreceptors and PARP activity is associated with oxidative 
DNA damage and the nuclear translocation of apoptosis inducing factor (AIF) (Paquet-
Durand, Silva et al. 2007). 
These observations in the Pde6b mutant rd1 mouse served as a basis for the present 
investigations on different Pde6a mutant mice. Experimental questions examined in 
particular are whether and how Pde6a gene defects lead to photoreceptor degeneration. 
What kind of mechanism participates in Pde6a mutation induced retinal degeneration, 
and what are the disease kinetics? In order to address these questions, in this study, we 
analyzed the effects of different mutations on Pde6 activity, the progression of the 
degeneration, and key mechanistic markers for retinal degeneration.  These descriptive 
studies were complemented with a set of interventional experiments designed to 
confirm mechanistic insights and highlight new avenues for potential future RP therapy 
development.  
4.2 Cell death mechanism in Pde6a mutants 
Although the TUNEL assay is a method widely used for the biochemical detection of 
apoptosis (Gavrieli, Sherman et al. 1992), it also readily detects necrotic and other forms 
of cell death (Grasl-Kraupp, Ruttkay-Nedecky et al. 1995). In this research, TUNEL 
positive cells are detected in the retinal photoreceptor cell layer of Pde6a mutant mice at 
around 9 days after birth. As retinal degeneration progresses, there is an obvious 
increase in the number of TUNEL positive cells, until almost all photoreceptor cells are 
lost. Although the TUNEL assay clearly labels the dying cells, it is not clear what kind of 
cell death mechanism leads up to it. Therefore, it is still necessary to conduct additional 
investigations into the exact nature of the underlying cell death pathways.  
Caspase is a major player in pathway of cell death. During apoptosis, PARP is cleaved 
and inactivated by Caspase-3, which prevents further repair of DNA damage and 
facilitates the execution of apoptosis (Gilliams-Francis, Quaye et al. 2003). But the 
broad-spectrum Caspase inhibitors are ineffective in limiting PARthanatos, which is 
caused by toxic accumulation of PAR in cytosol from over-activation of PARP as a unique 
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form of cell death (Andrabi, Dawson et al. 2008). Perhaps then Caspase does not play a 
substantial role during PARthanatos (Andrabi, Kim et al. 2006). This could explain why 
Caspase inhibitors failed to protect retinal photoreceptor cells in rd1 and P23H animal 
models (Liu, Ge et al. 1999, Yoshizawa, Kiuchi et al. 2002). We also show this point in 
our experiments, where we found cells positive for cleaved and activated Caspase-3 only 
rarely.  In fact, the numbers of Caspase-3 positive cells found in the retina of Pde6a mice 
were not significantly different from those detected in wt mice, indicating that in Pde6a 
animal models Caspase3 activity does not play a major role. Thus, this may be seen as 
additional proof that Pde6a mutation-induced photoreceptor cell death follows a non-
apoptotic route of cell death.  
Calpain, a kind of neutral cysteine protease, activated by Ca2+, plays a vital role in 
reconstruction of the cytoskeleton, cell differentiation, apoptosis, and signal 
transduction (Suzuki, Hata et al. 2004). Earlier experiments showed that the activation 
of Calpain plays a critical role in rd1 mouse retinal degeneration (Sancho-Pelluz, Arango-
Gonzalez et al. 2008, Paquet-Durand, Sanges et al. 2010). 
Calpain positive cells are detected in the retinal photoreceptor layer of animal models of 
all Pde6a mice at around P10 and their numbers were highly correlated with the 
progression of retinal degeneration. Calpain activity reaches its peak at P15 in ONL of 
V685M*R562W mice and R562W mice, at P12 in V685M, and at P21 in D670G mice. 
Compared to wt mice, it is increased significantly. This result indicates that Calpain 
activity may also play an important role in photoreceptor cell death in Pde6a mutant 
mice.  
Table 6.Gradient of different assays in Pde6a mutants in vivo 
 
  TUNEL.   V685M   (P12)   > V685M*R562W   (p15) & R562W  (P15)  >  D670G (P21) 
  Calpain. V685M    (p12)   > V685M*R562W   (p15) & R562W  (p15)  >  D670G (p21) 
  PARP.     V685M    (p12)   > V685M*R562W    (p13) > R562W  (p15)  >  D670G (p21) 
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Altogether, there were different degrees of cell death for the four Pde6a mutants and a 
gradient from higher to lower levels of affected photoreceptors was established in the 
order shown above. 
4.3 The role of PARP in retinal degeneration 
Poly (ADP-ribose) polymerase (PARP) belongs to a group of enzymes that are involved 
in many different functions, including regulation of gene transcription, cell death and 
survival (Kraus and Hottiger 2013). Similar to Calpains, an excessive activation of PARP 
plays a significant role in neurodegenerative diseases (Moncada and Bolanos 2006). 
PARP-1 is the most well-known enzyme of the PARP family. It’s mostly involved in 
damaged DNA repair to facilitate the repair process in both in vivo and in vitro (Dantzer, 
Ame et al. 2006). Furthermore, Photoreceptor cell death in several animal models 
including rd1, P23H, S334ter has been shown to be associated with excessive PARP 
activity (Kaur, Mencl et al. 2011). It has been suggested that PARP activation was 
connected to oxidative DNA damage. Furthermore, inhibition or knocking down of the 
PARP gene showed neuroprotection in different models for inherited retinal 
degeneration (Paquet-Durand, Silva et al. 2007, Sahaboglu, Tanimoto et al. 2010). This 
research also indicated that under normal conditions PARP activity contributes to the 
repair of such DNA damage. For instance, it participates in the death of retinal 
photoreceptor cells in a variety of rodent HRD models (Arango-Gonzalez, Trifunovic et 
al. 2014). However, the cell deaths that lead to photoreceptor degeneration in Pde6a 
mutants have not been well studied. 
Our experiments revealed that the number of PARP positive cells in animal models of 
Pde6a mice was increased as the degeneration progressed, reaching the peak at P12 in 
V685M, at P15 in R562W, and at P21 in D670G, respectively. What’s more, the TUNEL 
positive cells partially overlapped with the peak of PARP activation. Interestingly, PARP 
positive cells peaked on P13 in compound V685M*R562W animal models, 2 days before 
positive reaction in the TUNEL assay and Calpain activity. Hence, excessive activation of 
PARP may occur prior to retinal degenerative disease and accelerate cell death. At any 
rate, PARP activity clearly plays a key role in the cell death of retinal photoreceptor cells. 
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It is also hinted that the application of PARP inhibitors into retinal degenerative disease 
in the future could have a neuroprotective effect in targeted therapy. 
PJ34, a kind of newly researched and developed competitive PARP inhibitor, prevents 
the binding of NAD+ to the PARP enzyme, resulting in an inhibitory effect that is much 
stronger than previous PARP inhibitors. For example, that of traditional inhibitor-IC50 is 
200nM while that of PJ34 is only 20nM. However, its enzymatic activity reaches 10.000 
times of that of former (Suarez-Pinzon, Mabley et al. 2003). The molecular formula of 
PJ34 is C17H17N3O2. HCI, belonging to phenanthridine ketone compounds, it is water 
soluble, and has a high bioavailability when applied orally or intravenously. Research 
indicates that PJ34 plays an active role in many in vivo models, such as traumatic brain 
injury, myocardial infarction, Doxorubicin-induced myocardial failure, aging-associated 
heart failure, diabetic endothelial dysfunction, balloon angioplasty, endothelial injury by 
homocysteine, ARDS (Acute respiratory distress syndrome), hyperoxic lung injury, 
ovalbumin-induced asthma, mesenteric I/R injury, diabetic retinopathy and diabetic 
neuropathy (Garcia Soriano, Virag et al. 2001, Soriano, Pacher et al. 2001, Pacher, Cziraki 
et al. 2002, Pacher, Liaudet et al. 2002, Veres, Gallyas et al. 2003, Benko, Pacher et al. 
2004, Jagtap, Southan et al. 2004, Zheng, Szabo et al. 2004, Casey, Black et al. 2005) 
while it enhances endothelium dependency of myocardium in chronic heart failure, thus 
remarkably reducing cell quantities of necrosis and apoptosis (Fiorillo, Ponziani et al. 
2006). PJ34 also reduces photoreceptor cell death in rd1 retinal explants (Paquet-
Durand, Silva et al. 2007).  
PARP could influence intracellular Ca+ levels (Vosler, Brennan et al. 2008) through 
cellular pathways mediated by as of yet unknown PAR species. One pathway to cell 
death mediated by PARP could be through mitochondrial membrane depolarization and 
then open the mitochondrial permeability transition pores (MPTP) (Du, Zhang et al. 
2003). Afterward, opened MPTP in turn could cause a leakage of mitochondrial proteins 
into the cytosol, and translocate to the nucleus (Hong, Dawson et al. 2004). Finally, it 
would induce peripheral chromatin condensation and DNA damage (Wang, Dawson et 
al. 2009). With one route, PARP transforms DNA damage and can activate DNA repair 
processes and induce cell death. It has been suggested PARP over activation can lead to 
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cell death due to neurotoxicity caused by PAR accumulation (Wang, Shimoji et al. 2003). 
Therefore, the application of a PARP inhibitor could prevent the cell death signal 
pathway. The application of PJ34 in in vitro organotypic retinal explant cultures derived 
from Pde6a mutant animals has a significant neuroprotective effect in retinal 
photoreceptor cells. However, in the very fast V685M animal model, there is no 
significant difference in retinal photoreceptor cells in treatment and non-treatment 
groups. The cell death of photoreceptor cells in this animal model is the fastest, reaching 
the peak at P13. Perhaps, at P15, when we stopped the retinal explant culturing in those 
animal models it was already too late. Alternatively, it would also be possible that it was 
linked to a stronger genetic component. However, the treatment paradigm could be 
optimized to start before P11 and even earlier. Also, inhibiting only a single enzyme may 
not be enough to sufficiently protect the photoreceptor cells, which may continue to die 
through other PARP-independent mechanisms. Therefore, consideration should be given 
to combination therapy, such as the application of Calpain and PARP inhibitors together. 
4.4 Conclusion 
4.4.1 Alternative cell death routes involving Calpain and PARP 
In our studies, collectively, the analyzed markers (i.e. TUNEL, Calpain and PARP activity, 
PAR accumulation) coincided during their progression and followed a similar pattern in 
all four Pde6a mutants. These results have suggested that the cell death mechanisms 
triggered by different genetic mutations share a number of key components.   
Intracellular high Ca2+ levels can influence the metabolism of mitochondria, causing 
oxidative stress, activation of PARP and Calpain. Subsequently, nuclear DNA is in turn 
damaged by oxidative stress, while the excessive consumption of NAD+ and generation 
of PAR will have additional detrimental effects. Ca2+ inside the mitochondria is further 
imbalanced under the combined action of NAD+ reduction and PAR accumulation; and as 
a consequence, the cells undergo an energy deficit. The process of maintaining apoptosis 
is different according to the in vivo positioning of mitochondria, which may be involved 
in multiple cell death promoting pathways. Calpain activity may promote the release of 
AIF, hence the elimination or inhibition of Calpain may inhibit cell death or at least delay 
it (Andrabi, Dawson et al. 2008, Wang, Kim et al. 2009). The high activity of Calpain 
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emerges in each Pde6a mice model and therefore, the application of Calpain inhibitors to 
block Calpain activity may constitute another important target for the development of 
retinal degeneration therapy. 
Our studies identified activation of Calpain and PARP, as previously uncharacterized cell 
death signals in Pde6a mutants. Thus interfering with either Calpain or PARP may offer 
innovative therapeutic approaches for the treatment of cellular injury in RP. 
4.4.2 PARP as a therapeutic target in Pde6a retinitis pigmentosa 
Targeting critical factors of photoreceptor cell death could be a novel neuroprotective 
therapy in RP (Okoye, Zimmer et al. 2003). In order to test whether PARP was also 
responsible for photoreceptor loss caused by mutations in the Pde6a gene, we utilized 
three mouse models homozygous for the V685M, R562W and D670G mutation in Pde6a. 
Since homozygosity for mutant alleles is extremely rare in human RD patients, we also 
used compound heterozygous Pde6aV685M*R562W animals, which were genotype matched 
to human RP. In all four Pde6a mutant situations, we found an excessive activation of 
PARP, which correlated in time with the progression of photoreceptor degeneration. We 
then used organotypic retinal explant cultures treated with the PARP specific inhibitor 
PJ34 to confirm the causal involvement of PARP activity in the neurodegenerative 
process. The neuroprotective effect of PARP inhibition was evaluated for the different 
genetic conditions, at different treatment time-points and durations, to establish an 
optimal treatment regime for later in vivo application. Our results highlight PARP as a 
target for neuroprotective interventions in RP caused by Pde6a mutations and are a first 
attempt towards personalized, genotype matched therapy development for RP. 
4.4.3 Perspectives for future treatment developments 
The present study uncovered the role of Calpain and PARP activity during photoreceptor 
degeneration in four Pde6a animal models, and also found that short-term retinal 
cultures display increased photoreceptor survival after application of the PARP inhibitor 
PJ34. Still, blocking only one single enzyme may not be sufficient to prevent HRD 
entirely, as the photoreceptor cells may be able to die through other mechanisms. 
Therefore, future therapy developments may need to consider using combinations of 
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inhibitors of Calpain proteases and PARP, and possibly even further cellular targets 
involved in HRD.  
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5. Zusammenfassung  
Ziel. Retinitis Pigmentosa (RP) ist eine Gruppe heterogener Krankheiten, die zu 
Erblindung führt und in der Summe mit einer Häufigkeit von 1 in 4000 Individuen 
weltweit auftritt. RP ist gekennzeichnet durch eine hohe genetische Diversität, bei der 
Mutationen desselben Gens zu sehr verschiedenen Phänotypen führen können. Bisher 
lag der Fokus der Forschung auf Mutationen in Pde6b (Keeler 1924, Chang, Hawes et al. 
2002), während Pde6a Mutationen weit weniger untersucht wurden, obwohl sie 
ebenfalls zu Zelltod der Photorezeptor-Stäbchen führen und RP verursachen. 
Methoden. Die Experimente der vorliegenden Arbeit wurden in zwei Schritten durchgeführt: 
im ersten die Charakterisierung der retinalen Degeneration in vivo und im zweiten die in vitro 
Behandlung von Gewebe von Pde6a Mutanten. Für die Charakterisierung der retinalen 
Degeneration in vivo haben wir vier unterschiedliche homozygote Pde6a Mauslinien 
verwendet, und zwar  Pde6aV685M, Pde6aD670G,  Pde6aR562W und Pde6aV685M*R562W. Wir haben 
in den Pde6a Mauslinien mit den folgenden Markern den Fortschritt der Degeneration der 
Photorezeptoren beschrieben: - TUNEL-Signal, - Caspase-3, - Calpain-Aktivität, - PARP-
Aktivität und - PAR-Polymere. 2) Für eine Charakterisierung der Wirkung der Inhibition von 
PARP in vitro haben wir organotypische Kulturen von Retinas der verschiedenen Mauslinien 
verwendet. Diese Kulturen wurden mit dem pharmakologischen PARP Inhibitor PJ34 
behandelt, um zu bestätitigen, dass PARP-Aktivität eine Ursache des neurodegenerativen 
Prozesses ist.  
Ergebnisse. Unsere Untersuchung zeigt auf, dass das Tempo der retinalen Degeneration 
in vivo in den vier Pde6a Mutationen unterschiedlich ist und dass der Verlauf der 
Degeneration der Photorezeptoren immer korreliert ist mit erhöhten Signalen bei der 
Messung von TUNEL, PARP-Aktivität, PARylierten Proteinen und Calpain-Aktivität. Die 
Aktivität von Caspase-3 zeigte keine Erhöhung bei der retinalen Degeneration der Pde6a  
Mutanten. Der Einsatz eines pharmakologischen Inhibitors von PARP in organotypische 
Kulturen von Retinas von Pde6a Mäusen  bestätigte, dass PARP eine Rolle spielt in der 
retinalen Degeneration von Mäusen der vier Genotypen. Die neuroprotektive Wirkung 
des PARP Inhibitors wurde in den vier Genotypen zu verschiedenen Zeitpunkten und für 
verschiedene Expositionszeiten nachgewiesen. 
Ausblick. Wir konnten zeigen, dass die Enzyme Calpain und PARP im Verlauf der 
Degeneration der Photorezeptoren in verschiedenen Pde6a Mutanten eine zentrale Rolle 
spielen. Unsere Untersuchung unterstreicht, dass das PARP Enzym ein gemeinsames 
pharmakologisches Ziel sein kann für neuroprotektive Massnahmen in jenen Fällen der 
RP, denen Pde6a Mutationen zugrunde liegen. Darüber hinaus kann die vorliegende 
Studie dazu dienen, den Zeitverlauf der retinalen Degeneration bei RP Patienten 
vorherzusagen, deren RP unterschiedliche Pde6a Mutationen  zugrunde liegen, und die 
Studie kann helfen, den optimalen Zeitpunkt für klinische Intervention festzulegen.  
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